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Until 2007, the World Health Organization (WHO) 
recommended that bacille Calmette-Guérin (BCG) vaccination 
should be contraindicated in infants with symptomatic HIV 
disease in countries with a high burden of tuberculosis. This 
recommendation was based on the perceived low risk of 
serious adverse events in HIV-infected infants. The WHO 
revised its recommendations regarding BCG vaccination in 
HIV-infected infants in 2007, making HIV infection a full 
contraindication to BCG vaccination.1 BCG induces protective 
efficacy against tuberculous meningitis of 73% (67 - 79%) and 
against miliary disease of 77% (58 - 87%) in HIV-uninfected 
children.2 The efficacy against childhood pulmonary disease is 
variable;3 there is no evidence that BCG induces a protective 
effect against tuberculosis in HIV-infected infants and children.4 
BCG is a safe vaccine in immunocompetent infants, and severe 
vaccine adverse events in HIV-uninfected infants occur only 
with rare primary immune deficiencies in approximately 1 per 
million vaccinees.5 
The South African context and the risk 
of BCG adverse events in HIV-infected 
infants
BCG has been used in South Africa since 1973. Since 2001, a 
single dose of 0.05 ml BCG Danish strain (1331, Statens Serum 
Institute, Copenhagen) has routinely been given intradermally 
in the right deltoid region at birth to all infants, consistent with 
WHO guidelines. In the Western Cape Province, BCG coverage 
was 99% in 2005.6
Recent evidence shows that South African HIV-infected 
infants receiving BCG vaccination at birth are at increased 
risk of developing BCG adverse events. Up to 6% of children 
enrolled in a public access HIV treatment programme in the 
Western Cape experienced local or regional BCG adverse 
events (BCG adenitis).7 The incidence of the most severe 
adverse events, systemic or disseminated BCG (dBCG), is 
estimated at 992 per 100 000 HIV-infected infants, typically 
occurring at a median age of  7 - 8 months and with an all-
cause mortality of approximately 75%.8 Confirmed BCG 
dissemination has only been documented in infants with rapid 
HIV disease progression in the first year of life.9-11 
The Global Advisory Committee on Vaccine Safety (GACVS) 
and the Strategic Advisory Group of Experts (SAGE) reviewed 
data on BCG safety in HIV-infected infants in 2007 and 
recommended that BCG vaccination not be given to any 
HIV-infected infants, even in settings where tuberculosis is 
highly endemic.12,13 This revision was primarily based on the 
documented risk of dBCG disease in HIV-infected infants 
and not on the risk of local and regional BCG adverse events. 
Identification of HIV infection at birth, when BCG is often 
administered, is however not feasible owing to the limited 
sensitivity of early testing and the complicated logistics of 
repeat HIV-DNA polymerase chain reaction (PCR) testing. 
Routine diagnostic testing is performed from 6 weeks of 
age in South Africa and HIV-infected infants are usually 
asymptomatic at birth when given BCG.
BCG is also associated with immune reconstitution 
inflammatory syndrome (BCG IRIS), which usually presents 
as ipsilateral suppurative or non-suppurative regional adenitis 
following initiation of HAART. BCG IRIS, one of the most 
common forms of IRIS among South African HIV-infected 
infants, has low mortality but is associated with considerable 
morbidity.8,14-16 The southern African CHER trial of early versus 
delayed highly active antiretroviral therapy (HAART) in 
HIV-infected infants indicates that early initiation of HAART 
before 12 weeks of age and before clinical and immunological 
deterioration achieved a 76% reduction in infant mortality and 
a 75% reduction in HIV disease progression.17 Infants whose 
HAART was delayed until clinically or immunologically 
indicated had an incidence of BCG IRIS of 15.7%; early 
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HAART reduced the risk 3-fold to 5.2%.18 To date, most infants 
diagnosed with dBCG disease were not on HAART or were 
started on HAART shortly before presentation. These findings 
highlight the importance of early infant HIV diagnosis and the 
potential of early HAART in reducing the risk of BCG-related 
adverse events.
Risk in context
In 2006 the prevalence of HIV infection among pregnant South 
African women in the public sector was 29.4%19 and the annual 
incidence of tuberculosis was 940 per 100 000.20 In the Western 
Cape Province, the HIV-infected infant population at risk of 
developing serious BCG adverse events constituted 
approximately 1% of the total infant population ≤1 year of age 
during 2006.8 With a provincial maternal HIV prevalence of 
15.2% and documented vertical transmissions rate of 5.4%, we 
predicted 804 HIV-infected infants in 2006.8 Provided the 
maternal seroprevalence remains stable, the infant population 
at risk is likely to remain stable or decline. Vertical transmission 
rates in other provinces of South Africa are considerably 
higher, reflecting the need to strengthen prevention of mother-
to-child transmission (PMTCT) programmes nationally.  
However, HIV-infected infants (≤12 months of age) remain a 
small minority of all South African infants.
South African HIV-infected infants have a 20-fold higher 
risk of developing culture-confirmed tuberculosis disease 
compared with HIV-uninfected infants.21 There is no evidence 
of an excessive increase in disseminated tuberculosis compared 
with pulmonary tuberculosis in HIV-infected compared with 
uninfected infants.21 On the basis of the current evidence, the 
benefits of potentially preventing severe tuberculosis appear 
to be outweighed by the serious risks of BCG vaccine in the 
minority of HIV-infected infants, while in HIV-uninfected 
infants there is clear evidence of BCG benefits. No data exist 
regarding strategies to prevent tuberculosis in HIV-infected 
children who have not received BCG vaccination.
Challenges to implementation of 
revised BCG policy
There are potential risks of non-BCG vaccination in HIV-
exposed uninfected and HIV-unexposed infants. South 
African HIV-exposed infants have a high risk of exposure 
to tuberculosis early in life.22 Factors indicated by the WHO 
as requiring consideration when assessing the risk for HIV 
infection and implementing the GACVS recommendations 
include the prevalence of tuberculosis and the potential for 
infant exposure to Mycobacterium tuberculosis, prevalence of 
HIV infection, coverage and efficacy of PMTCT interventions 
(including early infant diagnosis), rates of exclusive and 
mixed breastfeeding, and the capacity to conduct follow-up of 
immunised children. Other important considerations include 
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good surveillance systems for tuberculosis and HIV, and good 
services for infant immunisation, child health, and treatment of 
HIV-infected children. 
A key consideration is the ability of infant vaccination 
and PMTCT programmes to allow for selectively delaying 
vaccination from birth until, for example, 10 - 14 weeks of age, 
following a negative HIV PCR testing result, e.g. at 4 - 6 weeks 
of age, and retaining infants for follow-up and vaccination 
when confirmed to be HIV-uninfected. In the Western Cape 
province, attendance for 14-week EPI vaccination visits was 
81.3% during 2005, indicating potential loss to follow-up 
of approximately 20% during the first 14 weeks of life even 
in this well-functioning programme. Selectively delayed 
BCG vaccination strategies in HIV-exposed infants could 
be combined with alternative strategies such as isoniazid 
preventive therapy in the intervening period. Although 
the available data do not demonstrate a benefit of primary 
isoniazid preventive therapy in the absence of a documented 
tuberculosis contact among HIV-exposed uninfected or HIV-
infected South African infants who received BCG at birth,23 
isoniazid preventive treatment is recommended in all infants 
who have a tuberculosis contact or proof of M. tuberculosis 
infection. 
Envisioned impact of policy change in 
South Africa 
Apart from reducing the considerable risk of BCG vaccination 
in a small proportion of HIV-infected infants, there is a 
potentially greater risk that the much larger proportion of HIV-
exposed yet uninfected infants will inadvertently not receive 
BCG if vaccination is selectively deferred. In South Africa 
such inadvertent non-vaccination of HIV-exposed uninfected 
infants may predispose them to an increase in disseminated 
tuberculosis. 
As PMTCT programmes are strengthened, the number 
of paediatric HIV infections should decline, resulting in an 
even smaller number of HIV-infected infants at risk of dBCG 
compared with a much larger pool of HIV-exposed uninfected 
and HIV-unexposed infants, who benefit from BCG vaccination. 
Early HIV testing and initiation of HAART in HIV-infected 
infants will soon be implemented in the Western Cape and it 
is hoped in the rest of South Africa, and will reduce all-cause 
mortality and the incidence of tuberculosis, BCG IRIS and 
possibly dBCG disease. 
Do conditions necessary for 
implementation of selectively delayed 
BCG vaccination exist in South Africa?
Successful implementation of a selective delayed BCG 
vaccination policy in HIV-exposed infants requires that all of 
the following conditions be met:
•    A high uptake of maternal HIV testing coupled with more 
effective PMTCT strategies including maternal HAART.
•    Consistent screening and management of tuberculosis in 
pregnant women.
•    Effective screening, diagnosis and management of 
tuberculosis in households with HIV-exposed infants.
•    High retention of HIV-exposed infants in public health care 
programmes. 
•    Early virological diagnosis of HIV infection in infants with 
rapid turnaround time for results.
•   Early institution of HAART in HIV-infected infants.
•    Co-ordination of PMTCT, vaccination and tuberculosis 
programmes to: (i) ensure BCG vaccination of all HIV-
uninfected infants; (ii) minimise loss to follow-up of all 
infants for vaccination and HIV testing; (iii) implement 
alternative tuberculosis preventive strategies; and (iv) 
deliver successful delayed vaccination following selective 
non-vaccination at birth.
These conditions do not currently exist in South Africa. Even 
where the required programmes are in place, major operational 
problems are present. Surveillance systems for tuberculosis and 
HIV and follow-up services for infants are often suboptimal. 
There is poor tuberculosis screening among HIV-infected 
pregnant women, who are at high risk of tuberculosis during 
the antenatal and postpartum periods.24 The situation should 
improve with roll-out and strengthening of PMTCT and 
HAART programmes and integration of maternal and infant, 
HIV and tuberculosis programmes. 
Paediatric public health practitioners, clinicians and 
researchers in paediatric tuberculosis and HIV, including 
the Western Cape Province Paediatric HIV/TB Policy 
Advisory Group, a provincial academic and public health 
technical advisory committee, and the International Union 
against Tuberculosis and Lung Diseases BCG Surveillance 
Working Group, have acknowledged the revised WHO 
recommendations.25 However, there is consensus among these 
individuals and committees that universal BCG immunisation 
of infants should continue in South Africa and other developing 
countries with high burdens of HIV and tuberculosis until all 
programmes are in place for preventing maternal tuberculosis 
and HIV infection and for safely implementing selective 
deferred vaccination of HIV-exposed infants. Regular review 
should be done of programme implementation considerations 
and new available data. PMTCT programmes should be further 
strengthened to reduce the number of HIV-infected infants.
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